CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Pitavastatin – a new inhibitor of the HMG-CoA reductase: peculiarities of clinical pharmacology and perspectives of its usage in treatment of cardiovascular diseases.
Authors
G. V. Dzyak
E. L. Kolesnik
K. Yu. Yegorov
Publication date
1 January 2013
Publisher
Dnipro State Medical University
Abstract
Cardiovascular mortality makes up 66.3 % of the total mortality in Ukraine. Myocardial infarction, stroke, atherosclerosis of peripheral arteries are the diseases caused by atherosclerosis and are prevalent in the mortality structure. One of the most effective means of successful prevention of cardiovascular disease are drugs that reduce the content of atherogenic lipids in the blood. Statins are the first line drugs for the treatment of patients with dyslipidemia and atherosclerosis in accordance with national and international guidelines. The article presents the features of the pharmacokinetics and pharmacodynamics, results of clinical trials and data on the efficacy and safety of a new inhibitor of the HMG-CoA reductase – pitavastatin (Livazo © (Recordati, Italy). Data from several multicenter randomized studies indicate that pitavastatin significantly reduces the level of cholesterol low-density lipoproteins and triglycerides, significantly increases the level of cholesterol high-density lipoproteins after 12 weeks of observation, and contributes to a significant regression of atherosclerotic plaques. It was shown that pitavastatin has a high level of safety and is well tolerated regardless of patients' age and racial origin. Pitavastatin is a new effective inhibitor of HMG -CoA reductase, which has been successfully used in many countries for the dyslipidemia treatment in patients with cardiovascular disease, diabetes, kidney diseases and other comorbid conditions
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Neliti
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:neliti.com:355287
Last time updated on 09/10/2022
Наукова періодика України
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ojs.journals.uran.ua:artic...
Last time updated on 20/06/2021